Bristol Glucophage Phase IV protocol release could impede study, Bristol asserts in case brought by HRG.

BRISTOL GLUCOPHAGE PHASE IV PROTOCOL RELEASE COULD DISRUPT STUDY, ATTORNEY Michael Petty (Fox, Bennett & Turner) asserted on behalf of Bristol-Myers Squibb during a Jan. 27 hearing in D.C. federal court. The hearing was held to consider summary judgment requests in a case brought against FDA by Public Citizen's Health Research Group seeking release of Bristol's protocol for a 10,000-patient study of the oral antidiabetic Glucophage (metformin) under the Freedom of Information Act. Bristol intervened in the suit as a defendant.